Clinical trials

Completed

An 8-week phase II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 24 or 32 week follow-up period to evaluate the efficacy of a formulation containing anti-oxidant of recombinant human nerve growth factor (rhNGF) 20 µg/ml, eye drops solution versus vehicle containing anti-oxidant, in patients with Stage 2 and 3 Neurotrophic Keratitis

NGF0214

What is the purpose of this study?

The purpose of study is to evaluate the safety and efficacy of rhNGF formulation containing anti-oxidant of recombinant human nerve growth factor (rhNGF) 20 µg/ml, eye drops solution versus vehicle containing anti-oxidant.

Trial overview

Condition

Neurotrophic Keratitis Stage 2 and 3

Study Identifiers

NCT02227147

Study type

Interventional
Randomized
Vehicle controlled

Intervention

Drug: rhNGF 20µg/ml or Vehicle

Phase

II

Start date

Jan 2015

End Date

Aug2016

Enrollment Goal

48 patients

Going deep into the trial

Eligibility/Recruitment

Age

≥18 years old

Gender

Accepts healthy volunteers

Key Criteria

close

Inclusion

close

Exclusion

close

Important Notes

Some information about patients involvement

Study participation will last approximately 32-40 weeks and will include up to 20 visits to the study center.

Desired Outcomes

close

Primary Outcomes

close

Secondary Outcomes

Find your nearest centre:

Loading...

loading...